Related Experiment Video
Updated: Feb 14, 2026
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Eight-hours adaptive deep brain stimulation in patients with Parkinson disease
Mattia Arlotti1, Sara Marceglia1, Guglielmo Foffani1
1From the Clinical Center for Neurotechnologies, Neuromodulation, and Movement Disorders (M.A., S.M., F.C., T.B., F.C., P.R., S.B.), Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milano; Dipartimento di Ingegneria e Architettura (S.M., M.P.), Università degli Studi di Trieste, Italy; CINAC (G.F.), Hospital Universitario HM Puerta del Sur, and Hospital Nacional de Parapléjicos, Toledo, Spain; Department of Neurology (J.V.), University of Wurzburg, Germany; Division of Neurosurgery (A.M.L.), University of Toronto, ON, Canada; Division of Neurology (E.M.), Centre Hospitalier Universitaire de Grenoble, France; Department of Medico-Surgical Sciences and Biotechnologies (F.C.), Sapienza University Rome Polo Pontino, Rome; and "Aldo Ravelli" Research Center (A.P.), Department of Health Sciences, University of Milan & Ospedale San Paolo, Milan, Italy.
Objectives:
To assess the feasibility and clinical efficacy of local field potentials (LFPs)-based adaptive deep brain stimulation (aDBS) in patients with advanced Parkinson disease (PD) during daily activities in an open-label, nonblinded study.
Methods:
We monitored neurophysiologic and clinical fluctuations during 2 perioperative experimental sessions lasting for up to 8 hours. On the first day, the patient took his/her daily medication, while on the second, he/she additionally underwent subthalamic nucleus aDBS driven by LFPs beta band power.
Results:
The beta band power correlated in both experimental sessions with the patient's clinical state (Pearson correlation coefficient r = 0.506, p < 0.001, and r = 0.477, p < 0.001). aDBS after LFP changes was effective (30% improvement without medication [3-way analysis of variance, interaction day × medication p = 0.036; 30.5 ± 3.4 vs 22.2 ± 3.3, p = 0.003]), safe, and well tolerated in patients performing regular daily activities and taking additional dopaminergic medication. aDBS was able to decrease DBS amplitude during motor "on" states compared to "off" states (paired t test p = 0.046), and this automatic adjustment of STN-DBS prevented dyskinesias.
Conclusions:
The main findings of our study are that aDBS is technically feasible in everyday life and provides a safe, well-tolerated, and effective treatment method for the management of clinical fluctuations.
Classification Of Evidence:
This study provides Class IV evidence that for patients with advanced PD, aDBS is safe, well tolerated, and effective in controlling PD motor symptoms.
More Related Videos
06:32Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
Published on: July 14, 2023
14:14Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
Published on: August 12, 2018
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:15Parkinson's Disease: Overview
01:23Holter Monitor: 24-Hour Monitoring
01:15Natural Selection and Adaptation
Beyond physical adaptations,...
01:12Adaptability of Cytoskeletal Filaments
01:21Introduction to Innate and Adaptive Immunity
Innate immunity is the body's natural, nonspecific defense system that acts quickly to protect against pathogens. It incorporates physical barriers like skin and mucous membranes and cellular elements such as phagocytes and natural killer cells. This part of our immune system provides an immediate,...